Physiomics Awarded New Contract
Physiomics awarded £47,600 contract for pharmacokinetic modelling on first-in-class bifunctional antibody therapy.
- Contract value £47,600
- Project duration three months
Select text to share a quote on X · sign in to keep highlights & notes in your PYC notes
Physiomics plc (AIM: PYC), a leading mathematical modelling, data science and biostatistics company supporting the development of new therapeutics and personalised medicine solutions, is pleased to announce a contract award with a new UK client.
The project will involve the application of modelling and simulation techniques to support the development of a first-in-class bifunctional antibody therapy designed to target multiple solid tumour indiciations. More specifically, Pharmacokinetic modelling approaches will be utilised to predict the human PK of the molecule in order to support the client to progress this new therapy into their first-in-human study. The project is valued at £47,600 and is projected to complete over the next three months.
Dr Peter Sargent, CEO of Physiomics, commented:
"We are delighted to be working with this new client and supporting their team with the development of their exciting new therapy. This new contract also reflects the progress Physiomics is making in expanding its client base and supporting the development of wider array of new oncology therapies through its services".
For more information about Physiomics and its services, please visit www.physiomics.co.uk.
Cleaned text: letterheads, contacts and legal notices removed. View the original announcement ↗ · Company filings. Not investment advice.